Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET

FENNEC PHARMACEUTICALS INC.

First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.
Management to host conference call at 8:30 a.m. ET on May 14; registration required for dial-in.
Webcast and replay archived on www.fennecpharma.com for 30 days.
PEDMARK received FDA approval in September 2022; PEDMARQSI approved in EU (June 2023) and UK (Oct 2023).
Company is commercial-stage specialty pharma focused on pediatric platinum-induced ototoxicity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.